Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Current Deferred Revenue (2025)

Organogenesis Holdings has reported Current Deferred Revenue over the past 1 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $3.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $3.9 million (changed N/A YoY), and the annual figure for FY2025 was $3.9 million, changed.
  • Current Deferred Revenue for Q4 2025 was $3.9 million at Organogenesis Holdings, up from $1.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ORGO hit a ceiling of $3.9 million in Q4 2025 and a floor of $1.5 million in Q3 2025.